Aveanna Healthcare Holdings Inc. (AVAH) Key Metrics
AVAH valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.69B
- Enterprise value
- $4.20B
- P/E (TTM)
- 9.8
- Forward P/E
- 13.3
- PEG ratio
- —
- Price / sales
- 1.0 10-yr median 0.4
- Price / book
- 9.7
- EV / EBITDA
- 13.8 10-yr median 12.3
- Dividend yield
- —
- Beta
- 1.95
AVAH key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAVAH valuation Price multiples at each fiscal year-end price.
AVAH returns How much profit the business earns on the capital it uses.
AVAH per-share figures Results divided by the shares outstanding at year-end.
AVAH financial health Debt, liquidity and how easily interest is covered.
AVAH efficiency & capital use Working capital cycle and where the cash goes.
AVAH valuation history
AVAH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AVAH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AVAH price vs earnings per share
AVAH key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Market capitalization | $1.76B | $881.5M | $509.1M | $144.7M | $1.37B | — | — | — |
| Enterprise value | $3.08B | $2.30B | $1.96B | $1.48B | $2.63B | — | — | — |
| P/E ratio | 7.8 | — | — | — | — | — | — | — |
| Price / sales | 0.7 | 0.4 | 0.3 | 0.1 | 0.8 | — | — | — |
| Price / book | 9.0 | — | — | — | 2.1 | — | — | — |
| Price / free cash flow | 15.3 | 33.5 | 30.7 | — | — | — | — | — |
| Price / operating cash flow | 14.4 | 27.0 | 22.5 | — | — | — | — | — |
| EV / sales | 1.3 | 1.1 | 1.0 | 0.8 | 1.6 | — | — | — |
| EV / EBITDA | 11.0 | 12.3 | 50.2 | — | — | — | — | — |
| EV / free cash flow | 26.8 | 87.4 | 118.6 | — | — | — | — | — |
| Earnings yield | 12.8% | −1.2% | −26.4% | −457.4% | −8.6% | — | — | — |
| Free cash flow yield | 6.5% | 3.0% | 3.3% | −41.7% | −2.0% | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | — | — | — |
| Share price at fiscal year-end | $8.17 | $4.57 | $2.68 | $0.78 | $7.40 | — | — | — |
| Per share | ||||||||
| Revenue per share | $11.32 | $10.50 | $9.98 | $9.63 | $9.09 | $8.04 | $7.45 | $6.96 |
| Earnings per share | $1.05 | −$0.06 | −$0.71 | −$3.57 | −$0.63 | −$0.31 | −$0.41 | −$0.26 |
| Operating cash flow per share | $0.57 | $0.17 | $0.12 | −$0.26 | −$0.06 | $0.63 | −$0.05 | $0.12 |
| Free cash flow per share | $0.53 | $0.14 | $0.09 | −$0.33 | −$0.15 | $0.55 | −$0.14 | $0.01 |
| Cash per share | $0.90 | $0.44 | $0.23 | $0.10 | $0.17 | $0.74 | $0.02 | $0.04 |
| Book value per share | $0.90 | −$0.63 | −$0.67 | −$0.02 | $3.45 | $1.44 | $1.46 | $1.91 |
| Tangible book value per share | −$4.74 | −$6.56 | −$6.72 | −$6.79 | −$7.04 | −$6.04 | −$5.43 | −$5.18 |
| Capex per share | $0.03 | $0.03 | $0.03 | $0.06 | $0.09 | $0.08 | $0.09 | $0.11 |
| Debt per share | $7.04 | $7.79 | $7.89 | $7.30 | $7.03 | $6.61 | $5.81 | $5.29 |
| Shares outstanding | 215.0M | 192.9M | 190.0M | 185.6M | 184.7M | 185.9M | 185.9M | 180.2M |
| Change in shares outstanding | +11.4% | +1.5% | +2.4% | +0.4% | −0.6% | 0.0% | +3.2% | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | 621.9% | — | — | — | −25.9% | −21.2% | −24.8% | −13.7% |
| Return on invested capital (ROIC) | 18.9% | 5.3% | 0.5% | −31.3% | −1.7% | −0.2% | 2.3% | 2.4% |
| Return on assets (ROA) | 12.2% | −0.7% | −8.1% | −32.7% | −5.6% | −3.3% | −4.9% | −3.0% |
| Return on tangible assets | 27.7% | −2.1% | −29.0% | −145.1% | −29.6% | −12.6% | −25.7% | −17.3% |
| Free cash flow margin | 4.7% | 1.3% | 0.9% | −3.4% | −1.6% | 6.8% | −1.8% | 0.2% |
| Income quality (OCF / net income) | 0.54 | — | — | — | — | — | — | — |
| Financial health | ||||||||
| Total debt | $1.51B | $1.50B | $1.50B | $1.36B | $1.30B | $1.23B | $1.08B | $952.4M |
| Cash & short-term investments | $193.3M | $84.3M | $43.9M | $19.2M | $30.5M | $137.3M | $3.3M | $8.0M |
| Net debt | $1.32B | $1.42B | $1.46B | $1.34B | $1.27B | $1.09B | $1.08B | $944.4M |
| Debt / equity | 7.79 | — | — | — | 2.04 | 4.60 | 3.98 | 2.76 |
| Debt / assets | 0.75 | 0.90 | 0.93 | 0.79 | 0.56 | 0.67 | 0.68 | 0.61 |
| Net debt / EBITDA | 4.74 | 7.57 | 37.15 | — | — | 17.75 | 24.31 | 9.83 |
| Current ratio | 1.32 | 0.98 | 0.89 | 0.83 | 0.81 | 1.31 | 1.11 | 1.08 |
| Quick ratio | 1.32 | 0.98 | 0.89 | 0.78 | 0.77 | 1.27 | 1.05 | 1.08 |
| Interest coverage | 1.9 | 0.9 | 0.1 | -6.0 | -0.5 | -0.0 | 0.4 | 0.5 |
| Working capital | $135.8M | −$9.5M | −$39.9M | −$56.7M | −$65.6M | $80.2M | $17.8M | $16.6M |
| Invested capital | $1.52B | $1.30B | $1.33B | $1.33B | $1.91B | $1.36B | $1.35B | $1.29B |
| Tangible asset value | −$1.02B | −$1.27B | −$1.28B | −$1.26B | −$1.30B | −$1.12B | −$1.01B | −$933.8M |
| Net current asset value | −$1.27B | −$1.39B | −$1.43B | −$1.45B | −$1.42B | −$1.24B | −$1.12B | −$991.0M |
| Graham number | $4.62 | — | — | — | — | — | — | — |
| Graham net-net per share | −$6.52 | −$7.74 | −$7.96 | −$8.19 | −$8.06 | −$6.98 | −$6.33 | −$5.89 |
| Capital allocation | ||||||||
| Share buybacks (net) | — | — | — | $0 | $0 | — | — | — |
| Capex / revenue | 0.3% | 0.3% | 0.3% | 0.7% | 1.0% | 1.0% | 1.2% | 1.6% |
| Capex / operating cash flow | 6.1% | 19.4% | 27.0% | — | — | 13.1% | — | 90.7% |
| Capex / depreciation | 0.26 | 0.20 | 0.20 | 0.31 | 0.45 | 0.50 | 0.62 | 1.64 |
| Stock-based compensation / revenue | 1.0% | 0.9% | 0.7% | 0.9% | 0.9% | 0.2% | 0.1% | 0.2% |
| SG&A / revenue | 21.6% | 23.3% | 25.0% | 27.1% | 25.0% | 23.7% | 24.6% | 25.7% |
| Efficiency | ||||||||
| Days sales outstanding | 44.3 | 47.2 | 45.4 | 46.0 | 44.2 | 42.1 | 45.7 | 53.1 |
| Days of inventory on hand | — | — | — | 4.3 | 4.1 | 3.7 | 1.9 | 0.0 |
| Days payables outstanding | 7.7 | 8.7 | 10.5 | 14.4 | 17.6 | 21.6 | 19.7 | 16.1 |
| Cash conversion cycle (days) | 36.7 | 38.4 | 34.9 | 36.0 | 30.7 | 24.3 | 27.9 | 37.0 |
| Receivables turnover | 8.23 | 7.74 | 8.04 | 7.93 | 8.27 | 8.66 | 7.98 | 6.87 |
| Payables turnover | 47.60 | 41.73 | 34.77 | 25.39 | 20.79 | 16.91 | 18.48 | 22.62 |
| Inventory turnover | — | — | — | 84.20 | 89.77 | 97.97 | 189.89 | 859,351,000.00 |
| Asset turnover | 1.32 | 1.24 | 1.14 | 0.88 | 0.80 | 0.87 | 0.88 | 0.81 |
| Average receivables | $295.5M | $261.7M | $235.7M | $225.5M | $203.1M | $172.6M | $173.4M | $182.4M |
| Average payables | $34.2M | $33.3M | $37.4M | $48.6M | $54.6M | $61.5M | $52.2M | $38.0M |
| Average inventory | — | — | — | $14.7M | $12.7M | $10.6M | $5.1M | $1 |
| Intangibles / total assets | 59.9% | 68.8% | 71.2% | 73.3% | 83.0% | 75.4% | 81.1% | 82.5% |
Computed from AVAH's annual financial statements (latest annual report filed March 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AVAH valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Aveanna Healthcare traded at 7.8 times earnings. Based on the latest twelve months, the trailing P/E is 9.8 and the forward P/E is 13.3. Aveanna Healthcare earned a return on equity of 621.9% and a return on invested capital of 18.9% in fiscal 2025. It ended the year with $1.5 billion of debt and $193.3 million in cash and short-term investments, net debt of $1.3 billion. The share count rose 19.3% from 180.2M to 215.0M over 7 years.
See the AVAH income statement, the AVAH chart for price history, or the AVAH stock overview for the latest quote and news.
AVAH key metrics FAQ
What is Aveanna Healthcare's P/E ratio?
Aveanna Healthcare's trailing P/E ratio is 9.8 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 13.3. At the end of fiscal 2025 it was 7.8.
What is Aveanna Healthcare's EV/EBITDA?
Aveanna Healthcare's enterprise value was 11.0 times EBITDA at the end of fiscal 2025 (enterprise value $3.1 billion, EBITDA $279.0 million); the current EV/EBITDA is 13.8.
What is Aveanna Healthcare's return on equity?
Aveanna Healthcare's return on equity (ROE) was 621.9% in fiscal 2025: net income of $225.0 million on average shareholders' equity of $36.2 million.
What is Aveanna Healthcare's ROIC?
Aveanna Healthcare's return on invested capital was 18.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Aveanna Healthcare have?
Aveanna Healthcare had total debt of $1.5 billion at the end of fiscal 2025, a debt-to-equity ratio of 7.79 and $1.3 billion of net debt (4.74 times EBITDA).
What is Aveanna Healthcare's free cash flow yield?
Aveanna Healthcare generated $114.8 million of free cash flow in fiscal 2025, a free cash flow yield of 6.5% on its market value at year-end ($1.8 billion).
What is Aveanna Healthcare's current ratio?
Aveanna Healthcare's current ratio was 1.32 at the end of fiscal 2025: current assets were 1.32 times current liabilities.